CMMB Articles, Chemomab Therapeutics Ltd. - From 06/06/24

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug...

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company d...

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company d...

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology compan...

—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discu...

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Chol...

Chemomab Therapeutics Ltd (NASDAQ:CMMB) shares are trading on a strong volume session volume of 6.1 million, compared to an average volume of ...

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced a...

Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings. Children'...

Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. Palo Alto Networks reported qu...